Swiss drug major Roche Holding AG (RHHBY) announced Wednesday that the phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer or ES-SCLC did not meet its co-primary endpoint of progression-free survival.
The trial evaluated the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial or first-line treatment for people with ES-SCLC.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com